The National Council for Behavioral Health has released a new pamphlet titled “Guide to Long-Acting Medications for Providers and Organizations.” By downplaying some aspects of the available science, the pamphlet implicitly acts as a promotional tool for the pharmaceutical industry.
A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.
Researchers question biases of preliminary trials that found that sodium nitroprusside, an antihypertensive drug, has positive effects on schizophrenia symptoms.
Researchers examine how rapid discontinuation can mimic the relapse of mental health symptoms and confound psychiatric drug studies.
A new study provides an insider’s look into how psychiatrists view the establishment of drug-free programs in Norway.
Twice as many teenagers with ADHD experienced severe psychosis when taking Adderall, as compared to Ritalin, according to a new study.
A new study examines the effects of CBD as an adjunct therapy to antipsychotic medication for patients diagnosed with schizophrenia.
A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
Researchers reveal the limitations and misleading interpretations of two recent studies that claim to demonstrate that long-term antipsychotic use leads to better outcomes.
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
Mixed-Methods study explores the experiences of antipsychotic discontinuation among service users.
A recent paper published in Schizophrenia Bulletin reported on a meta-analysis of antipsychotic drugs which found that a significant number of people do not experience a remission of psychotic symptoms. The evidence base suggests that it is time for us to reappraise the effectiveness of these drugs and shift our practice patterns accordingly.
A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.
A systematic review of the limited research available on the long-term effects of antipsychotics finds fewer symptoms in those off of the drugs.
Researchers review the risks and benefits of deprescribing from antipsychotic drugs and advocate for a patient-centered approach to tapering.
Antipsychotics are big business, professionals are often at a loss as to how to help people going through disturbing experiences, the voices of patients are crowded out of the equation — there are many reasons for the lack of real education and informed consent around antipsychotics. To address this gap in knowledge, we launched a world study on antipsychotic medication withdrawal.
Researchers point to the risks of using antipsychotics with youth and caution against the practice.
People who reduced antipsychotic use by tapering were doing just as well after five years as those who continued using the drugs.
New intervention shows promise in reducing over-prescription of off-label antipsychotics in older adults.
Research investigates clinicians’ perspectives on best care practices and the complicated realities of providing care in the face of agency limitations and mechanized interventions.
Study finds that reduced cortical thickness and brain surface area associated with 'schizophrenia' may result from antipsychotic drug use.
Study details Medicaid-insured birth cohort’s exposure to psychiatric medications and mental health services.
Members of the U.S. Food and Drug Administration’s Psychiatry Products division go on the defensive in a new article, responding to concerns about the agency’s approval of digital aripiprazole.
The most important data in an RCT is not whether the drug provides a statistically significant benefit over placebo. The most important data is the “number needed to treat” calculation (NNT). For the person considering taking an antidepressant or an antipsychotic, the NNT data provides the “math” needed to weigh the potential benefit of taking the drug against the potential harm of doing so.